Skip to main content

dabogratinib

Generic: Dabogratinib·Code: TYRA-300

dabogratinib: sourced relationships with 1 company · 4 clinical trials tracked.

dabogratinib evidence translation

What we can confirm

What it means

Source-backed records connect dabogratinib to TYRA; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could dabogratinib → TYRA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Related indications

Low-grade NMIBC; Locally Advanced Urothelial Carcinoma; AchondroplasiaLow Grade Upper Tract Urothelial CarcinomaAchondroplasiaAdvanced Solid TumorBladder CancerMetastatic Urothelial CarcinomaSolid TumorUrothelial Carcinoma

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
Tyra Biosciences, Inc. (TYRA)
developer · Reported 2024-03-19 · Current development: unknownSource
Low-grade NMIBC; Locally Advanced Urothelial Carcinoma; Acho…
Phase 1/Phase 2
Tyra Biosciences, Inc. (TYRA)
developer · Reported 2026-03-02 · Current development: unknownSource
Low Grade Upper Tract Urothelial Carcinoma
Phase 2
Clinical Trial Registry Records (4)

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)

NCT07265947Registry updated 2026-10-13·Phase 2·TYRA
Recruiting

Primary endpoint: To assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants)

InterventionalRandomizedopen230 targetStarted 2025-12Completion 2030-1132 sites · France, Israel, Spain, United StatesTyra Biosciences, Inc

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

NCT06995677Registry updated 2026-09-29·Phase 2·TYRA
Recruiting

Primary endpoint: To assess the efficacy of TYRA-300 in LG IR-NMIBC participants

InterventionalRandomizedopen90 targetStarted 2025-06Completion 2028-0948 sites · Australia, Italy, Spain, United StatesTyra Biosciences, Inc

A Multicenter, Phase 2, Dose-Escalation/Dose-Expansion Study of TYRA-300 in Children With Achondroplasia With Open Growth Plates: BEACH301

NCT06842355Registry updated 2026-10-01·Phase 2·TYRA
Recruiting

Primary endpoint: Incidence of treatment-related adverse events as assessed by CTCAE v5.0

Interventionalopen92 targetStarted 2025-03Completion 2030-0625 sites · Australia, Canada, France, Netherlands…Tyra Biosciences, Inc

A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)

NCT05544552Registry updated 2026-01-12·Phase 1/Phase 2·TYRA
Active, not recruiting

Primary endpoint: Phase 1 Part A: To determine the maximum tolerated doses (MTD).

Interventionalopen310 targetStarted 2022-11Completion 2027-0619 sites · Australia, France, Spain, United StatesTyra Biosciences, Inc

Frequently asked questions

Which companies have sourced relationships with dabogratinib?

dabogratinib has dated SEC/FDA relationship records for Tyra Biosciences, Inc..

How many clinical trials involve dabogratinib?

BioSniper tracks 4 clinical trials involving dabogratinib.